Posted by Michael Wonder on 06 Apr 2018
MorphoSys announces approvals for Tremfya (guselkumab) for the treatment of moderate-to-severe plaque psoriasis in Brazil and Australia
5 April 2018 - MorphoSys announced today that country subsidiaries of its licensee Janssen reported that Tremfya (guselkumab) has been approved for the treatment of adults living with moderate to severe plaque psoriasis in Brazil and Australia.
As reported by Janssen-Cilag Farmacêutica Ltda. (Janssen), the Brazilian National Health Surveillance Agency ("ANVISA") has approved Tremfya for the treatment of adults living with moderate to severe plaque psoriasis. Janssen-Cilag Pty Limited (Janssen) announced that Tremfya has been approved by the TGA and registered on the Australian Register of Therapeutic Goods for the treatment of adults living with moderate to severe plaque psoriasis in Australia.
Tremfya is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology.
